Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19

Condition:   Coronavirus Infections Interventions:   Drug: tixagevimab/cilgavimab 150+150 mg;   Drug: tixagevimab/cilgavimab 300+300 mg;   Drug: regdanvimab Sponsors:   City Clinical Hospital No.52 of Moscow Healthcare Department;   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials